Effects of Semaglutide versus Bariatric Surgery on Noninvasive Markers of Hepatic Steatosis and Fibrosis in Obesity with MASLD

Clicks: 26
ID: 326702
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #76 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: Obesity is a key driver of metabolic dysfunction-associated steatotic liver disease (MASLD). Beyond lifestyle modification, pharmacological and surgical therapies were recently established. This study compared the effects of lifestyle therapy, lifestyle plus semaglutide, and bariatric surgery on non-invasive markers of hepatic steatosis and fibrosis. MATERIALS AND METHODS: In this single-center, prospective, observational cohort study, ninety-two adults with obesity were analyzed over 72 weeks. Patients received (1) lifestyle-based multimodal therapy ([LIFESTYLE], n = 30), (2) lifestyle plus semaglutide therapy ([SEMA], n = 30, semaglutide 1.0 ± 0.4 mg/week), or (3) lifestyle plus laparoscopic sleeve gastrectomy (LSG) ([SURGERY], n = 32). Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were assessed using FibroScan®; Fibrosis-4 (FIB-4) and FibroScan-AST (FAST)-scores were calculated. RESULTS: At baseline, all patients showed hepatic steatosis. Over 72 weeks, CAP decreased significantly (p < 0.001) with reduction of -17.9 ± 14.0 [LIFESTYLE], -46.0 ± 14.0 [SEMA], and -83.7 ± 10.0 dB/m [SURGERY], respectively (overall p = 0.002). Baseline LSM differed between groups and declined by -0.8 ± 1.0, -2.8± 0.8, and -4.9 ± 1.1 kPa, respectively (overall p < 0.001), without significant differences between SEMA and SURGERY in relative reduction (p = 0.428). FAST scores decreased significantly over time across all groups (p < 0.001). FIB-4 increased modestly after SURGERY (+0.29; p < 0.001), while remaining stable in SEMA and LIFESTYLE (both p > 0.3). Weight loss amounted to -4.2 ± 1.8, -10.7 ± 1.5 and -31.6 ± 1.5%. LSM improvement was weight-dependent in SURGERY (p = 0.027), while LSM improvement in SEMA occurred independently of weight change (p = 0.508). CONCLUSIONS: Semaglutide and LSG both improved non-invasive markers for hepatic steatosis and fibrosis, whereas lifestyle intervention alone showed limited benefit. Despite differing degrees of weight loss, adjusted liver stiffness did not differ significantly between semaglutide and surgery, a hypothesis-generating finding that warrants further investigation into weight-independent mechanisms.
Reference Key
openalex_W7204447705 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Paula Lünswilken, Katarzyna Worobiec, Lara Braun, Julia Altrogge, Andrea Schenk, Lina Jegodzinski, Britta Wilms, Jens U Marquardt, Svenja Meyhöfer
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag350
URL
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgag350/70818330/dgag350.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.